Meet Our Team
Our experienced leadership team has a deep research focus and leverages diverse perspectives to BioMimetix’s clinical and company development. With a CEO that has over 40 years of experience in developing and discovering metalloporphyrins, the team is passionate about advancing this new drug class to transform the treatment of cancer.Strong, Reseach-Focused Team








James Crapo, MD
CEO

Rob Hellewell
President & Chief Business Officer

David S Silberstein, PhD
VP of R&D

Shayne Gad, PhD
VP of Drug Safety, Regulatory Affairs

Robert Ogden, CPA
CFO

Sara Penchev
Director of Clinical Operations

David MacLeod, PhD
Director of Information Science & Data Management

John Wetzel, PhD
Director, Chemistry, Manufacturing and Controls